Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Santoni

Showing results (341-350 of 404) with videos related to

Pageof 41
Sort By:
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
European Urology Oncology|June 3, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter ExperienceGiuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
The Journal of Urology|November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinomaRoberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Pageof 41

Showing results (341-350 of 404) with videos related to

Sort By:
Pageof 41
Clinical & Experimental Metastasis|February 16, 2024
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinationsMichele Maffezzoli, Matteo Santoni, Giulia Mazzaschi, et al.
European Urology Oncology|June 3, 2025
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter ExperienceGiuseppina Bruno, Maria Iole Natalicchio, Marianna Garofoli, et al.
JCO Global Oncology|July 8, 2025
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 StudyMimma Rizzo, Andrey Soares, Shilpa Gupta, et al.
The Journal of Urology|November 30, 2014
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinomaRoberto Iacovelli, Alessio Farcomeni, Cora N Sternberg, et al.
Cancer Medicine|February 21, 2025
Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective ExperienceMimma Rizzo, Franco Morelli, Yüksel Ürün, et al.
Targeted Oncology|August 6, 2024
Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 ProjectAlessandro Rizzo, Fernando Sabino Marques Monteiro, Yüksel Ürün, et al.
Cancers|January 30, 2019
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal CancerCarlo Capalbo, Francesca Belardinilli, Domenico Raimondo, et al.
Plos One|January 4, 2014
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyDaniele Santini, Giuseppe Procopio, Camillo Porta, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 6, 2022
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief CommunicationSebastiano Buti, Umberto Basso, Diana Giannarelli, et al.
International Journal of Cancer|November 4, 2025
Toxicity-related immunotherapy discontinuation and outcome in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1 study)Javier Molina-Cerrillo, Giandomenico Roviello, Maria T Bourlon, et al.
Pageof 41